AOD-9604
Half-life
30 min
Time to Peak
15 min
Steady State
~1 days
Dose Range
250–500 mcg
Frequency
Daily
Overview
Modified fragment of human growth hormone (hGH fragment 177-191) with a tyrosine residue added. Targets fat metabolism without the growth-promoting effects of full GH. Originally studied for obesity treatment but failed Phase II trials. Now used in wellness/peptide community for fat loss. Limited clinical PK data. Requires reconstitution with BAC water.
Mechanism of Action
Mimics the lipolytic (fat-burning) region of growth hormone without affecting IGF-1 levels or blood sugar. Stimulates lipolysis and inhibits lipogenesis in adipose tissue.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Subcutaneous (SubQ) | 250–500 mcg | 30 min | 15 min | Daily |
Storage & Handling
2-8C — Store lyophilized powder refrigerated. Reconstitute with BAC water. Use reconstituted solution within 4-6 weeks.
Used in Regimens
AOD-9604 is not currently part of any catalog regimen.
Data Sources
- Peer-reviewed AOD-9604 Phase II obesity trial results
Related Tools
Track AOD-9604 with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.